(OTC BB: NNVC.OB) (the "Company"), announced today that the Company's
CEO, Eugene Seymour, MD, MPH has been invited as a panelist at the 2nd Annual
Livingston Healthcare Summit on September 24th, 2009 in New York City.
Dr. Seymour will join other industry panelists in the “Drug Discovery
and Development” session to discuss early to mid-stage financing and pharmaceutical
alliance challenges and trends. The panelists and participants include pharmaceutical
and biotech decision makers and executives, investors, government and regulatory
agency representatives from a number of countries.
This is a unique, by invitation conference, designed to bring together key
stakeholders from pharmaceutical, finance and investment, business strategy,
as well as governmental science and regulatory segments, according to Conference
Chair, Mostafa Analoui, PhD, Head of Healthcare and Life Sciences at Livingston
“This is an important opportunity to network with significant decision-makers
in our industry,” said Dr. Seymour.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company
that is creating special purpose nanomaterials for viral therapy. The Company's
novel nanoviricide™ class of drug candidates are designed to specifically
attack enveloped virus particles and to dismantle them. The Company is developing
drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird
flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the
eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and
Ebola virus, among others.